Adenoviruses are widely used for overexpressing proteins in primary mammalian cells. Incorporation of the early viral gene, E1A, or viral cross-contamination can occur during amplification, and identification of these products is crucial as the transcription of unwanted genetic material can impact cell function and compromise data interpretation. Here we report methods for evaluation of contaminating adenovirus and E1 viral DNA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149638 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0023160 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.
J Immunother Cancer
January 2025
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
Background: Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its potential antitumor effects in several preclinical renal cancer models.
View Article and Find Full Text PDFCharacteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer.
Mol Cancer Ther
November 2024
University of California, Los Angeles, Los Angeles, CA, United States.
The treatment of non-small cell lung cancer has made major strides with the use of immune checkpoint inhibitors, but there remains a significant need for therapies that can overcome immunotherapy resistance. Dendritic cell (DC) vaccines have been proposed as a therapy that can potentially enhance the antitumor immune response. We have embarked on a phase I clinical trial of a vaccine consisting of monocyte-derived DCs (moDCs) modified to express the chemokine CCL21 (CCL21-DC) given in combination with pembrolizumab.
View Article and Find Full Text PDFEngineering an oncolytic adenoviral platform for precise delivery of antisense peptide nucleic acid to modulate PD-L1 overexpression in cancer cells.
Int J Pharm
January 2025
Department of Pharmacy, University of Naples Federico II, via D. Montesano 49, Naples 80131, Italy.
Cancer immunotherapy is focused on stimulating the immune system against cancer cells by exploiting immune checkpoint mechanisms. PD-1/PD-L1 is one of the most known immune checkpoints due to the widespread upregulation of the Programmed Death Ligand 1 (PD-L1) transmembrane protein in cancer tissues. Accordingly, taking advantage of the ability of oncolytic adenoviruses (OAd) to specifically infect and kill tumor cells over healthy ones, here, we developed a targeted delivery platform based on OAd to selectively deliver in cancer cells an antisense peptide nucleic acid (PNA) targeting the PD-L1 mRNA.
View Article and Find Full Text PDFNovel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment.
J Nanobiotechnology
October 2024
Department of Urology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China.
Recombinant oncolytic adenovirus offers a novel and promising cancer treatment approach, but its standalone efficacy remains limited. This study investigates a combination treatment strategy by co-administering recombinant oncolytic Adv-loaded silk hydrogel with a PD-L1 inhibitor for patients with bladder cancer to enhance treatment outcomes. Bladder cancer tissues from mice were collected and subjected to single-cell sequencing, identifying CRB3 as a key gene in malignant cells.
View Article and Find Full Text PDFRecombinant adenoviruses expressing HPV16/18 E7 upregulate the HDAC6 and DNMT3B genes in C33A cells.
Front Cell Infect Microbiol
October 2024
Faculty of Medicine, School of Basic Medical Sciences, Dalian University of Technology, Dalian, China.
Article Synopsis
- High-risk human papillomavirus (HPV) is linked to cervical, anal, and oral cancers due to its E6 and E7 proteins, which are crucial for transforming normal cells into cancerous ones, but their effects on cellular processes are still not completely understood.!
- Researchers created recombinant viruses to express HPV16/18 E6 and E7 genes in C33A cells, using RNA sequencing to analyze the impact of these genes on host gene expression related to cervical cancer.!
- The study found that HPV16/18 E6/E7 overexpression increased levels of several cancer-related genes, with specific correlations to pathways involved in DNA replication and tumor proliferation, suggesting a detailed relationship between these proteins and cancer progression.!
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!